IL6 and acute respiratory distress syndrome: Their findings support the use of XBJ in ARDS and severe pneumonia as evidenced by reduced mortality rates [risk ratio, 0.64 (95% credible interval (CrI), 0.54–0.77)], reduced ICU stay times [mean difference (MD), −4.51 (95% CrI, −4.97–−4.06)], reduced TNF-α [(MD), −1.23 (95% CrI, −1.38–−1.08)] and IL-6 [(MD), −1.15 (95% CrI, −1.52–−0.78)] levels [72].